Imaging Lymph Nodes and Heart After a Heart Attack
Uses scans and blood tests to study immune response in adults after a heart attack.
Key facts
- Who runs it
- Wuerzburg University Hospital
- Where
- Würzburg, GermanySee the 2 sites
- Trial code
- Registry title
- Lymphatic Organs and Myocardium After Myocardial Infarction
- Status
- Recruiting
- People taking part
- 57 people, planned
- Started
- 1 Apr 2022
- Expected to end
- Dec 2026
- Type of study
- Interventional
- Treatments tested
- Multimodality Imaging
- Record updated
- 25 May 2023
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who have had a heart attack (STEMI) and were treated with an immediate heart catheter procedure. They must have a stable clinical course. Scans will study the immune response.
- Age
- 18 to 90 years
- Sex
- Men and women
- Disease stage
- Acute heart attack (STEMI) treated with immediate catheterization, with a stable clinical course
- Earlier treatment
- Immediate catheterization for the heart attack. No immunosuppressive therapy.
Main reasons for not taking part
- Unstable circulation more than 48 hours after the catheter procedure
- Known coronary artery disease or known structural heart disease
- Multi vessel disease or NSTEMI
- Sarcoidosis, immunosuppressive therapy or acute inflammatory disease
- Pregnancy or breast-feeding
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- patients with acute myocardial infarction (STEMI) who were treated with immediate catheterization
- stable clinical course
- male/female, above 18 years old
Who cannot take part
- immunosuppressive therapy
- known structural heart disease
- multi vessel disease
- acute inflammatory disease
- active cardiac implants, ferromagnetic implants
- hemodynamic instablity > 48 h after immediate catherization
- known CAD
- NSTEMI
- sarcoidosis
- no consent obtainable
- contraindiations for CMR
- impaired renal function
- pregnancy, breast-feeding
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 90 years old?
Where in Germany
- Klinikum Würzburg Mitte, Medizinische KlinikWürzburg, GermanyContact: Willibald Hochholzer, ProfessorTaking people
- University Hospital WuerzburgWürzburg, GermanyContact: Theresa ReiterTaking people
About the trial
What the trial wants to find out
The adaptive immune response plays an important role in myocardial healing and remodeling after acute myocardial infarction in patients. Therefore, the involved lymphocytes represent a novel target for therapeutic interventions. However, there are no established blood-derived biomarkers to predict the quantity and quality of the adaptive immune response to cardiac injury. Multimodal imaging of the heart and immunologic organs might provide such information.
Read full original descriptionShow less
Recent retrospective analysis of patients after MI revealed enlarged mediastinal lymph nodes associated with increased CXCR4 radiotracer accumulation, thereby indicating that CXCR4 PET-based lymph node imaging provides a non-invasive quantitative readout of the local adaptive immune response. These considerations are further fuelled by the fact that, within lymph nodes, CXCR4 is expressed almost exclusively on lymphocytes, whereas various other cell types express CXCR4 within the myocardium.
This leads to the hypothesis that the size of mediastinal lymph nodes and their respective CXCR4 PET signals correlate with the adaptive immune response to cardiac injury and might provide predictive information for functional cardiac decline during follow-up.
This prospective clinical study will use multimodal imaging to monitor chemokine receptor 4 (CXCR4) expression in the lymph nodes, myocardium, spleen, and bone marrow after acute MI. The combination of cardiac magnetic resonance (CMR), echocardiography, and positron emission tomography (PET) along with blood collection for immunophenotyping will allow to determine i) if the size of mediastinal lymph nodes and their respective PET-derived CXCR4 signals at baseline correlate with the adaptive immune response to acute cardiac injury; and ii) if they predict cardiac adverse remodelling during longitudinal follow-up.
The group in the trial
- Multimodal imagingOther group
Multimodal imaging approach. This includes a CXCR4 targeted PET/CT (\[68Ga\]Pentixafor) during the acute hospital stay, and serial CMR and Echo imaging.
Treatment: Multimodality Imaging
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Multimodal Characterization of Lymphatic Organs and Myocardium in Patients After Acute Myocardial Infarction
- Plain-language title
- Imaging Lymph Nodes and Heart After a Heart AttackGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT05519735, who can take part
- Record updated
- 25 May 2023